Grants and funding for social organisations

Enhancing Mobility for All: affordable, reliable, and accessible multimodal transport for inclusive rural and urban connectivity – Societal Readiness pilot

European Union · EU

Enhancing Mobility for All: affordable, reliable, and accessible multimodal transport for inclusive rural and urban connectivity – Societal Readiness pilot

Period: 3/6/2027 – —

Enhancing Resilience and Accuracy in Positioning, Navigation, and Timing (PNT) Systems and e-conspicuity solutions

European Union · EU

Enhancing Resilience and Accuracy in Positioning, Navigation, and Timing (PNT) Systems and e-conspicuity solutions

Period: 3/6/2027 – —

Support for dissemination events in the field of Transport Research

European Union · EU

Support for dissemination events in the field of Transport Research

Period: 3/6/2027 – —

Innovative microgrids for improved energy system integration and efficiency in urban contexts

European Union · EU

Innovative microgrids for improved energy system integration and efficiency in urban contexts

Period: 9/2/2027 – —

Hydrogen cities

European Union · EU

Hydrogen cities

Period: 9/2/2027 – —

Inclusive and climate resilient multimodal passenger hubs enhancing modal shift towards sustainable transport and shared mobility

European Union · EU

Inclusive and climate resilient multimodal passenger hubs enhancing modal shift towards sustainable transport and shared mobility

Period: 9/2/2027 – —

Boosting the transformation towards climate-neutral cities, the net-zero economy and open strategic autonomy through Pre-Commercial Procurement (PCP)

European Union · EU

Boosting the transformation towards climate-neutral cities, the net-zero economy and open strategic autonomy through Pre-Commercial Procurement (PCP)

Period: 9/2/2027 – —

Advancing circular logistics solutions in cities

European Union · EU

Advancing circular logistics solutions in cities

Period: 9/2/2027 – —

HORIZON EUROPE - Soutenir la mise en œuvre de la mission « Villes intelligentes et neutres sur le plan climatique » - 2027

France · FR

Who can apply Commune · Intercommunalité / Pays · Département · Région · Collectivité d’outre-mer à statut particulier · Etablissement public dont services de l'Etat · Entreprise publique locale (Sem, Spl, SemOp)

Horizon Europe - 2021-2027 ----- 92,32 millions d'euros ----- Budget total de l'appel : 92,32 millions d'euros Budget par topic : HORIZON-MISS-2027-04-CIT-01 : 20 millions d'euros HORIZON-MISS-2027-04-CIT-02 : 5 millions d'euros HORIZON-MISS-2027-04-CIT-03 : 18 millions d'euros HORIZON-MISS-2027-04-CIT-CCRI-04 : 22,50 millions d'euros HORIZON-MISS-2027-04-CIT-05 : 26,82 millions d'euros Montant de la subvention : entre 5 et 12 millions d'euros Taux de financement : jusqu'à 100 % du total des coûts éligibles ----- Certains financements au titre du programme Horizon Europe sont structurés en réponse à des ambitions politiques (« destinations ») et déployés à travers des appels à propositions (« Calls for proposals ») ciblant des thématiques ou secteurs plus précis (« Topics »). Ainsi, votre candidature doit être directement reliée à un topic d’un appel à propositions. Différentes catégories de projets sont éligibles : RIA, Research and Innovation Actions : Recherche basique et appliquée / Développement et adoption de technologies / Essai et validation d'un prototype en laboratoire ; IA, Innovation Actions : Prototypes, tests, démonstrations, projets pilotes, placement sur le marché. Ces actions peuvent inclure un volet limité aux activités de R&D ; CSA, Coordination and Support Actions : Réseautage, études & conférences, communication, études pour de nouvelles infrastructures de recherche ; MSCA, Marie Skłodowska-Curie Actions / Bourses ERC : Réseaux de formation pour les chercheurs, Bourses individuelles pour les chercheurs expérimentés, Echange de personnels – mobilité pour les chercheurs et le personnel non scientifique. De même, les appels précisent les bénéficiaires attendus : Projets collaboratifs, composés d’un coordinateur et des partenaires (consortium) ; Projets mono-bénéficiaires, impliquant une seule organisation ; Bourses individuelles, ouvertes à des personnes physiques en leur nom propre avec leur établissement de rattachement. TOPICS : A venir HORIZON-MISS-2027-04-CIT-01 : Micro-réseaux innovants pour une meilleure intégration et une plus grande efficacité des systèmes énergétiques en milieu urbain HORIZON-MISS-2027-04-CIT-02 : Villes à hydrogène HORIZON-MISS-2027-04-CIT-03 : Pôles multimodaux de transport de passagers inclusifs et résilients au changement climatique, favorisant le transfert modal vers des transports durables et la mobilité partagée HORIZON-MISS-2027-04-CIT-CCRI-04 : Promouvoir des solutions logistiques circulaires dans les villes HORIZON-MISS-2027-04-CIT-05 : Stimuler la transformation vers des villes neutres sur le plan climatique, une économie à zéro émission nette et une autonomie stratégique ouverte grâce aux achats publics avant commercialisation (PCP) Informations complémentaires Pour trouver votre Point de Contact National (NCP) : Cliquez ici Utile Lignes directrices (EN) : Cliquez ici Autres documents de l’appel (EN) : Cliquez ici Site web de la DG (EN) : Cliquez ici Plus d’informations (EN) : Cliquez ici

Period: 9/2/2027 – —

Translational Efforts to Advance Gene-based Therapies for Ultra-Rare Neurological and Neuromuscular Disorders (U01 - Clinical Trial Optional)

United States · US

Who can apply Native American tribal organizations (other than Federally recognized tribal governments) · City or township governments · State governments · Special district governments · Others (see text field entitled "Additional Information on Eligibility" for clarification) · Private institutions of higher education · Public and State controlled institutions of higher education · Native American tribal governments (Federally recognized) · Independent school districts · For profit organizations other than small businesses · County governments · Small businesses · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · Public housing authorities/Indian housing authorities

The Ultra-Rare Gene-Based Therapy (URGenT) network supports Investigational New Drug (IND)-enabling studies and planning activities for First-in-Human (FIH) clinical testing of gene-based or transcript-directed therapeutics, such as oligonucleotides and viral-based gene therapies, for ultra-rare neurological or neuromuscular disorders. The goal of this announcement is to accelerate the development of a promising clinical candidate with robust biological rationale and demonstrated proof of concept (POC) data for the intended approach in a model system relevant to a specified patient population towards an IND filing and the initiation of a clinical trial.

Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01 Clinical Trial Not Allowed)

United States · US

Who can apply County governments · Public and State controlled institutions of higher education · Independent school districts · Small businesses · Native American tribal organizations (other than Federally recognized tribal governments) · Others (see text field entitled "Additional Information on Eligibility" for clarification) · State governments · Private institutions of higher education · City or township governments · Special district governments · For profit organizations other than small businesses · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · Native American tribal governments (Federally recognized) · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · Public housing authorities/Indian housing authorities

This Funding Opportunity Announcement (FOA) encourages the submission of applications that propose to advance research in cancer etiology and early detection biomarkers, utilizing the advantages of the unique biorepository resources of the NCI-sponsored Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial. The PLCO Biorepository offers high-quality, prospectively collected, serial pre-diagnostic blood samples from the PLCO screened arm participants, and a onetime collection of buccal cells from the control arm participants. Available data associated with the biospecimens includes demographic, diet, lifestyle, smoking, screening results, and clinical data. This FOA supports a wide range of cancer research including, but not limited to, biochemical and genetic analyses of cancer risk, as well as discovery and validation of early detection biomarkers. The proposed research project must involve use of PLCO biospecimens; additionally, it should also take advantage of the unique characteristics of the PLCO biospecimens. Research projects that do not involve the use of PLCO biospecimens will not be supported under this FOA.

NIDCD Research Grants for Translating Basic Research into Clinical Practice (R01 Clinical Trial Optional)

United States · US

Who can apply Public housing authorities/Indian housing authorities · Special district governments · State governments · Public and State controlled institutions of higher education · Small businesses · Native American tribal governments (Federally recognized) · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · For profit organizations other than small businesses · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · City or township governments · Others (see text field entitled "Additional Information on Eligibility" for clarification) · Private institutions of higher education · County governments · Independent school districts · Native American tribal organizations (other than Federally recognized tribal governments)

This Funding Opportunity Announcement (FOA) is intended to provide an avenue for basic scientists, clinicians and clinical scientists to jointly initiate and conduct translational research projects which translate basic research findings into clinical tools for better human health. The scope of this FOA includes a range of activities to encourage translation of basic research findings which will impact the diagnosis, treatment and prevention of communication disorders. Connection to the clinical condition must be clearly established and the outcomes of the grant must have practical clinical impact.

NCI Pathway to Independence Award (K99/R00 Clinical Trial Required)

United States · US

Who can apply City or township governments · Small businesses · Native American tribal organizations (other than Federally recognized tribal governments) · State governments · Others (see text field entitled "Additional Information on Eligibility" for clarification) · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · County governments · Native American tribal governments (Federally recognized) · Special district governments · Public housing authorities/Indian housing authorities · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · Independent school districts · Private institutions of higher education · For profit organizations other than small businesses · Public and State controlled institutions of higher education

The purpose of the NCI Pathway to Independence Award (K99/R00) program is to facilitate a timely transition of talented postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NCI research support during this transition in order to help awardees to launch competitive, independent research careers.

NCI Pathway to Independence Award (K99/R00 Clinical Trial Not Allowed)

United States · US

Who can apply Native American tribal organizations (other than Federally recognized tribal governments) · Small businesses · Public and State controlled institutions of higher education · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · Native American tribal governments (Federally recognized) · Public housing authorities/Indian housing authorities · County governments · Private institutions of higher education · Others (see text field entitled "Additional Information on Eligibility" for clarification) · Special district governments · Independent school districts · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · State governments · For profit organizations other than small businesses · City or township governments

The purpose of the NCI Pathway to Independence Award (K99/R00) program is to facilitate a timely transition of talented postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NCI research support during this transition in order to help awardees to launch competitive, independent research careers.

Ajuts per compensar la paralització temporal d'activitats pesqueres 2026 (FEMPA)

AUTONOMICA - CATALUÑA - DEPARTAMENT D'AGRICULTURA, RAMADERIA, PESCA I ALIMENTACIÓ ·

Agricultura, Pesca y Alimentación

Early Stage Testing of Pharmacologic or Neuromodulatory Device-based Interventions for the Treatment of Mental Disorders (R33- Clinical Trial Required)

United States · US

Who can apply State governments · Public housing authorities/Indian housing authorities · Special district governments · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · For profit organizations other than small businesses · County governments · Small businesses · Others (see text field entitled "Additional Information on Eligibility" for clarification) · Native American tribal governments (Federally recognized) · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · Private institutions of higher education · City or township governments · Public and State controlled institutions of higher education · Independent school districts · Native American tribal organizations (other than Federally recognized tribal governments)

NIMH requires an experimental therapeutics approach for the development and testing of therapeutic interventions, in which studies both evaluate the clinical effect of an intervention and generate information about the mechanisms underlying a disorder or an intervention response. As part of NIMHs Clinical Trial Pipeline, this NOFO encourages early stage testing of pharmacologic interventions with novel mechanisms of actions or device-based interventions. More specifically, this NOFO is intended to support early stage testing of pharmacologic or device-based interventions using a protocol design where the presumed mechanism of action of the intervention is adequately tested, to provide meaningful information where target modulation yields a dose-dependent neurophysiological/clinical/behavioral effect.

Effectiveness Trials to Test Mental Health System Interventions (R61/R33 Clinical Trial Required)

United States · US

Who can apply Native American tribal governments (Federally recognized) · For profit organizations other than small businesses · State governments · Independent school districts · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · Public and State controlled institutions of higher education · Special district governments · Public housing authorities/Indian housing authorities · Native American tribal organizations (other than Federally recognized tribal governments) · Others (see text field entitled "Additional Information on Eligibility" for clarification) · Private institutions of higher education · Small businesses · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · County governments · City or township governments

This R61/R33 concept complements NIMHs suite of clinical trial NOFOs by supporting feasibility and infrastructure development (R61) followed by well-powered clinical trials (R33) to test the effectiveness of system interventions and strategies for improving the organization, delivery, coordination, and clinical and functional outcomes of mental health services. System interventions - which may span, for example, structural, policy, organizational, and interpersonal domains - attend to issues about the access, equity, engagement/utilization, value (cost/financing), management, or quality and safety of mental health services, with the goal of improved care processes and clinical and functional outcomes. Accordingly, the focus of system interventions may include a variety of care settings, such as health systems and organizations, mental health and community clinics, schools, and child welfare or juvenile justice systems

Full-Scale Hybrid Effectiveness-Implementation Trials for Mental Health Interventions (R01 - Clinical Trial Required)

United States · US

Who can apply Native American tribal governments (Federally recognized) · Native American tribal organizations (other than Federally recognized tribal governments) · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · State governments · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · Small businesses · Public and State controlled institutions of higher education · County governments · Others (see text field entitled "Additional Information on Eligibility" for clarification) · City or township governments · Public housing authorities/Indian housing authorities · Special district governments · Independent school districts · Private institutions of higher education · For profit organizations other than small businesses

Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (R01 Clinical Trial Required). This NOFO is a key element of NIMHs set of NOFOs to support clinical trials research across the intervention development and testing pipeline. The NOFO supports (1) clinical trials to test the effectiveness of optimized therapeutic and preventive interventions for use in community and practice settings; and (2) clinical trials to evaluate the effectiveness of patient-, provider-, organizational-, or systems-level services interventions to improve access, continuity, quality, equity, and/or value of mental health services. This NOFO is intended to support trials that: address a significant problem, such that the findings have potential to inform practice; are adequately powered to definitively answer the primary research question(s), with well-justified hypotheses supported by pilot data; and are designed to examine questions regarding mediators and moderators of effects. Consistent with the NIMH experimental therapeutics approach, this NOFO is intended to support effectiveness trials that explicitly address whether the intervention engages the target(s)/mechanism(s) presumed to underlie the intervention effects (i.e., the mechanism(s) that accounts for changes in clinical/functional outcomes, changes in provider behavior, improved access or continuity of services, etc.). The collaborative R01 mechanism provides support for multisite trials when two or more sites are necessary for completion of the trial (e.g., to increase sample size, accelerate recruitment, or increase sample diversity and representation).

Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R33 Clinical Trial Required)

United States · US

Who can apply Others (see text field entitled "Additional Information on Eligibility" for clarification) · Special district governments · Native American tribal governments (Federally recognized) · Private institutions of higher education · Small businesses · City or township governments · Public housing authorities/Indian housing authorities · County governments · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · Native American tribal organizations (other than Federally recognized tribal governments) · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · Independent school districts · State governments · Public and State controlled institutions of higher education · For profit organizations other than small businesses

Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R33 Clinical Trial Required). As part of NIMH's clinical trials pipeline, this NOFO encourages pilot research developing and testing novel psychosocial interventions and/or targets. Consistent with NIMH's emphasis on the experimental therapeutics approach to intervention development, it intends to speed the translation of emergent research in basic, behavioral, cognitive, affect, and neuropsychological science into preventative or therapeutic interventions. This RFA will provide up to three years of support to replicate target engagement from prior studies and to test the association between target engagement and change in clinical outcome(s).

Pilot Hybrid Effectiveness-Implementation Trials for Mental Health Interventions (R01 Clinical Trial Required)

United States · US

Who can apply Special district governments · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · County governments · Independent school districts · For profit organizations other than small businesses · Small businesses · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · Others (see text field entitled "Additional Information on Eligibility" for clarification) · City or township governments · Public and State controlled institutions of higher education · Native American tribal organizations (other than Federally recognized tribal governments) · Public housing authorities/Indian housing authorities · Private institutions of higher education · State governments · Native American tribal governments (Federally recognized)

Pilot Effectiveness Trials for Treatment, Preventive and Services Interventions (R01 Clinical Trial Required). As part of NIMH's clinical trials pipeline NOFOs, this announcement encourages pilot effectiveness studies focused on 1) optimizing the effectiveness of preventive and therapeutic interventions with previously demonstrated efficacy, for use with broader target populations or for use in community practice settings, and 2) developing and preliminary testing innovative services interventions. Consistent with the NIMH experimental therapeutics approach, this NOFO is intended to support pilot studies of intervention effectiveness or service delivery approaches that explicitly address whether the intervention engages the target(s)/mechanism(s) presumed to underlie the intervention effects (i.e., the mechanism(s) that accounts for changes in clinical/functional outcomes, changes in provider behavior, improved access or continuity of services, etc.).

Confirmatory Efficacy Clinical Trials of Non-Pharmacological and Pharmacological Interventions for Mental Disorders (R01 Clinical Trial Required)

United States · US

Who can apply Others (see text field entitled "Additional Information on Eligibility" for clarification) · City or township governments · Public housing authorities/Indian housing authorities · For profit organizations other than small businesses · Small businesses · Independent school districts · Native American tribal governments (Federally recognized) · Native American tribal organizations (other than Federally recognized tribal governments) · Private institutions of higher education · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · Special district governments · State governments · County governments · Public and State controlled institutions of higher education · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education

Confirmatory Efficacy Clinical Trials of Non-Pharmacological Interventions for Mental Disorders (R01 Clinical Trial Required). As part of NIMH's clinical trials pipeline NOFOs, this announcement supports confirmatory efficacy testing of non pharmacological therapeutic and preventive interventions for mental disorders in adults and children that address unmet therapeutic needs, and are consistent with the NIMH emphasis on the experimental therapeutics approach. In this approach, clinical trials should be designed to increase knowledge of the relationship between underlying disease processes and the mechanisms of action through which any intervention produces therapeutic change.

Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R61/R33 Clinical Trial Required)

United States · US

Who can apply Native American tribal organizations (other than Federally recognized tribal governments) · Others (see text field entitled "Additional Information on Eligibility" for clarification) · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · Private institutions of higher education · Public and State controlled institutions of higher education · Small businesses · Independent school districts · Public housing authorities/Indian housing authorities · County governments · State governments · Native American tribal governments (Federally recognized) · For profit organizations other than small businesses · City or township governments · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · Special district governments

Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R61/R33 Clinical Trial Required). As part of NIMH's clinical trials pipeline, this NOFO encourages pilot research developing and testing novel psychosocial interventions and/or targets. Consistent with NIMH's emphasis on the experimental therapeutics approach to intervention development, it intends to speed the translation of emergent research in basic, behavioral, cognitive, affect, and neuropsychological science into preventative or therapeutic interventions. This RFA will provide up to two years of support for evaluation of target engagement and establishment of intervention parameters, and up to three years of support to replicate target engagement from prior studies and to test the association between target engagement and change in clinical outcome(s).

First in Human and Early Stage Clinical Trials of Novel Investigational Drugs or Neuromodulatory Device-based Interventions for Psychiatric Disorders (U01 Clinical Trial Required)

United States · US

Who can apply Native American tribal organizations (other than Federally recognized tribal governments) · Small businesses · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · Special district governments · Others (see text field entitled "Additional Information on Eligibility" for clarification) · Public and State controlled institutions of higher education · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · County governments · Independent school districts · City or township governments · Native American tribal governments (Federally recognized) · Public housing authorities/Indian housing authorities · For profit organizations other than small businesses · Private institutions of higher education · State governments

The purpose of this Notice of Funding Opportunity (NOFO) is to encourage cooperative agreement applications to support early stage clinical trials of novel mechanism of action, investigational drugs, or novel neuromodulatory devices for the treatment of psychiatric disorders in areas of unmet medical need. The NOFO will support milestone-driven early stage trials in pediatric and adult populations. First in human (FIH) and Phase II studies of novel agents must assess target engagement (brain exposure), pharmacological effects, safety, and tolerability to assess feasibility for Phase II/proof of concept (PoC) studies in psychiatric disorders. Phase II/PoC studies must evaluate the drugs impact on clinically relevant physiological systems (functional measures) and clinical indicators of effect. The NOFO also supports FIH and early feasibility studies (EFS) of novel devices to evaluate target engagement, safety, tolerability, and efficacy. The overall objective is to facilitate rapid collection of data to "de-risk" novel mechanism of action investigational drugs, novel drugs for use in pediatric populations with psychiatric disorders, and devices or combination treatments in order to attract private or other public funding for further clinical development as FDA-approved treatments. A key aspect of this NOFO is the formation of collaborative partnerships between the biomedical researchers and biotechnology or industry researchers to facilitate psychiatric drug or device development.

Early Stage Testing of Pharmacologic or Neuromodulatory Device-based Interventions for the Treatment of Mental Disorders (R61/R33 Clinical Trial Required)

United States · US

Who can apply Native American tribal governments (Federally recognized) · Independent school districts · City or township governments · State governments · Small businesses · Public housing authorities/Indian housing authorities · Native American tribal organizations (other than Federally recognized tribal governments) · Public and State controlled institutions of higher education · For profit organizations other than small businesses · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · County governments · Special district governments · Private institutions of higher education · Others (see text field entitled "Additional Information on Eligibility" for clarification)

NIMH requires an experimental therapeutics approach for the development and testing of therapeutic interventions, in which studies both evaluate the clinical effect of an intervention and generate information about the mechanisms underlying a disorder or an intervention response. As part of NIMHs Clinical Trial Pipeline, this NOFO encourages early stage testing of pharmacologic interventions with novel mechanisms of actions or device-based interventions. More specifically, this NOFO is intended to support early stage testing of pharmacologic or device-based interventions using a protocol design where the presumed mechanism of action of the intervention is adequately tested, to provide meaningful information where target modulation yields a dose-dependent neurophysiological/clinical/behavioral effect.